PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1534240
PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1534240
Global GLP-1 Analogues Market Size study, by Product, by Format, by Route of Administration, by Indication, by End User and Regional Forecasts 2022-2032
Global GLP-1 Analogues Market is valued at approximately USD 35.59 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 33% over the forecast period 2024-2032. GLP-1 analogue drugs have witnessed significant acceptance, particularly after their benefits in chronic obesity and weight management became widely known. This class of drugs, referred to as incretin mimetics, aids in regulating blood glucose levels and promoting satiety, making them crucial in treating diabetes and obesity. The market is driven by a strong R&D pipeline, with many key players developing innovative products and novel indications.
The GLP-1 analogues market is experiencing robust growth due to a strong research and development (R&D) pipeline aimed at advancing treatments for type 2 diabetes and obesity. Pharmaceutical companies are heavily investing in developing new and improved GLP-1 receptor agonists to enhance efficacy, safety, and patient convenience. For example, Novo Nordisk is exploring once-weekly oral formulations of semaglutide, which have shown promising results in reducing HbA1c levels and promoting weight loss. Additionally, Eli Lilly's tirzepatide, a dual GIP/GLP-1 receptor agonist, has demonstrated superior efficacy in clinical trials compared to existing GLP-1 therapies. These advancements are fueling the market's expansion, as companies strive to address the growing global burden of diabetes and obesity. Moreover, the extended therapeutic uses and development of oral GLP-1 Analogues present various lucrative opportunities over the forecast years. However, the high entry barriers due to duopoly and non-adherence to therapy are challenging the market growth throughout the forecast period of 2024-2032.
The key regions considered for Global GLP-1 Analogues Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is a dominating region in the Global GLP-1 Analogues Market in terms of revenue. The market growth in the region is being attributed to factors including the high prevalence of type 2 diabetes and obesity, advanced healthcare infrastructure, and the strong presence of key pharmaceutical companies such as Novo Nordisk, Eli Lilly, and Pfizer. Whereas, the market in the Asia Pacific is anticipated to grow at the fastest rate over the forecast period fueled by the increasing prevalence of diabetes and obesity, rising healthcare awareness, and improving access to advanced medical treatments. Countries such as China and India are witnessing a surge in diabetes cases due to urbanization, sedentary lifestyles, and changing dietary habits, driving the demand for effective diabetes management solutions.
Major market player included in this report are:
- Novo Nordisk A/S
- Eli Lilly and Company
- Sanofi
- AstraZeneca
- Boehringer Ingelheim International GmbH
- Innovent
- Hanmi Pharm
- Zealand Pharma A/S
- Pfizer, Inc.
- GlaxoSmithKline plc
- Johnson & Johnson
- Merck & Co., Inc.
- Teva Pharmaceutical Industries Ltd.
- Bristol-Myers Squibb Company
- Roche Holding AG
The detailed segments and sub-segment of the market are explained below:
By Product:
- Ozempic
- Wegovy
- Rybelsus
- Saxenda
- Victoza
- Trulicity
- Mounjaro
- Zepbound
- Soliqua
- Xultophy
- Bydureon
- Other products
By Format:
- Single-dose
- Multi-dose
- Tablets
By Route of Administration:
- Subcutaneous
- Oral
By Indication:
- Diabetes
- Obesity
- Other indications
By End User:
- Hospitals and Specialty Clinics
- Long-term Care Facilities
- Home Care Settings
By Region:
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- France
- Spain
- Italy
- ROE
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- RoAPAC
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Saudi Arabia
- South Africa
- RoMEA
Years considered for the study are as follows:
- Historical year - 2022
- Base year - 2023
- Forecast period - 2024 to 2032
Key Takeaways:
- Market Estimates & Forecast for 10 years from 2022 to 2032.
- Annualized revenues and regional level analysis for each market segment.
- Detailed analysis of geographical landscape with Country level analysis of major regions.
- Competitive landscape with information on major players in the market.
- Analysis of key business strategies and recommendations on future market approach.
- Analysis of competitive structure of the market.
- Demand side and supply side analysis of the market.
Table of Contents
Chapter 1. Global GLP-1 Analogues Market Executive Summary
- 1.1. Global GLP-1 Analogues Market Size & Forecast (2022-2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
- 1.3.1. By Product
- 1.3.2. By Format
- 1.3.3. By Route of Administration
- 1.3.4. By Indication
- 1.3.5. By End User
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion
Chapter 2. Global GLP-1 Analogues Market Definition and Research Assumptions
- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
- 2.3.3.1. Availability
- 2.3.3.2. Infrastructure
- 2.3.3.3. Regulatory Environment
- 2.3.3.4. Market Competition
- 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
- 2.3.4.1. Regulatory frameworks
- 2.3.4.2. Technological Advancements
- 2.3.4.3. Environmental Considerations
- 2.3.4.4. Consumer Awareness & Acceptance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates
Chapter 3. Global GLP-1 Analogues Market Dynamics
- 3.1. Market Drivers
- 3.1.1. Strong R&D Pipeline
- 3.1.2. Increasing Prevalence of Chronic Diseases
- 3.2. Market Challenges
- 3.2.1. High Entry Barriers Due to Duopoly
- 3.2.2. Non-adherence to Therapy
- 3.3. Market Opportunities
- 3.3.1. Extended Therapeutic Uses
- 3.3.2. Development of Oral GLP-1 Analogues
Chapter 4. Global GLP-1 Analogues Market Industry Analysis
- 4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
- 4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
- 4.3. Top Investment Opportunity
- 4.4. Top Winning Strategies
- 4.5. Disruptive Trends
- 4.6. Industry Expert Perspective
- 4.7. Analyst Recommendation & Conclusion
Chapter 5. Global GLP-1 Analogues Market Size & Forecasts by Product 2022-2032
- 5.1. Segment Dashboard
- 5.2. Global GLP-1 Analogues Market: Product Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 5.2.1. Ozempic
- 5.2.2. Wegovy
- 5.2.3. Rybelsus
- 5.2.4. Saxenda
- 5.2.5. Victoza
- 5.2.6. Trulicity
- 5.2.7. Mounjaro
- 5.2.8. Zepbound
- 5.2.9. Soliqua
- 5.2.10. Xultophy
- 5.2.11. Bydureon
- 5.2.12. Other products
Chapter 6. Global GLP-1 Analogues Market Size & Forecasts by Format 2022-2032
- 6.1. Segment Dashboard
- 6.2. Global GLP-1 Analogues Market: Format Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 6.2.1. Single-dose
- 6.2.2. Multi-dose
- 6.2.3. Tablets
Chapter 7. Global GLP-1 Analogues Market Size & Forecasts by Route of Administration 2022-2032
- 7.1. Segment Dashboard
- 7.2. Global GLP-1 Analogues Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 7.2.1. Subcutaneous
- 7.2.2. Oral
Chapter 8. Global GLP-1 Analogues Market Size & Forecasts by Indication 2022-2032
- 8.1. Segment Dashboard
- 8.2. Global GLP-1 Analogues Market: Indication Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 8.2.1. Diabetes
- 8.2.2. Obesity
- 8.2.3. Other indications
Chapter 9. Global GLP-1 Analogues Market Size & Forecasts by End User 2022-2032
- 9.1. Segment Dashboard
- 9.2. Global GLP-1 Analogues Market: End User Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 9.2.1. Hospitals and Specialty Clinics
- 9.2.2. Long-term Care Facilities
- 9.2.3. Home Care Settings
Chapter 10. Global GLP-1 Analogues Market Size & Forecasts by Region 2022-2032
- 10.1. North America GLP-1 Analogues Market
- 10.1.1. U.S. GLP-1 Analogues Market
- 10.1.1.1. Product breakdown size & forecasts, 2022-2032
- 10.1.1.2. Format breakdown size & forecasts, 2022-2032
- 10.1.1.3. Route of Administration breakdown size & forecasts, 2022-2032
- 10.1.1.4. Indication breakdown size & forecasts, 2022-2032
- 10.1.1.5. End User breakdown size & forecasts, 2022-2032
- 10.1.2. Canada GLP-1 Analogues Market
- 10.1.1. U.S. GLP-1 Analogues Market
- 10.2. Europe GLP-1 Analogues Market
- 10.2.1. U.K. GLP-1 Analogues Market
- 10.2.2. Germany GLP-1 Analogues Market
- 10.2.3. France GLP-1 Analogues Market
- 10.2.4. Spain GLP-1 Analogues Market
- 10.2.5. Italy GLP-1 Analogues Market
- 10.2.6. Rest of Europe GLP-1 Analogues Market
- 10.3. Asia-Pacific GLP-1 Analogues Market
- 10.3.1. China GLP-1 Analogues Market
- 10.3.2. India GLP-1 Analogues Market
- 10.3.3. Japan GLP-1 Analogues Market
- 10.3.4. Australia GLP-1 Analogues Market
- 10.3.5. South Korea GLP-1 Analogues Market
- 10.3.6. Rest of Asia Pacific GLP-1 Analogues Market
- 10.4. Latin America GLP-1 Analogues Market
- 10.4.1. Brazil GLP-1 Analogues Market
- 10.4.2. Mexico GLP-1 Analogues Market
- 10.4.3. Rest of Latin America GLP-1 Analogues Market
- 10.5. Middle East & Africa GLP-1 Analogues Market
- 10.5.1. Saudi Arabia GLP-1 Analogues Market
- 10.5.2. South Africa GLP-1 Analogues Market
- 10.5.3. Rest of Middle East & Africa GLP-1 Analogues Market
Chapter 11. Competitive Intelligence
- 11.1. Key Company SWOT Analysis
- 11.2. Top Market Strategies
- 11.3. Company Profiles
- 11.3.1. Novo Nordisk A/S
- 11.3.1.1. Key Information
- 11.3.1.2. Overview
- 11.3.1.3. Financial (Subject to Data Availability)
- 11.3.1.4. Product Summary
- 11.3.1.5. Market Strategies
- 11.3.2. Eli Lilly and Company
- 11.3.3. Sanofi
- 11.3.4. AstraZeneca
- 11.3.5. Boehringer Ingelheim International GmbH
- 11.3.6. Innovent
- 11.3.7. Hanmi Pharm
- 11.3.8. Zealand Pharma A/S
- 11.3.9. Pfizer, Inc.
- 11.3.10. GlaxoSmithKline plc
- 11.3.11. Johnson & Johnson
- 11.3.12. Merck & Co., Inc.
- 11.3.13. Teva Pharmaceutical Industries Ltd.
- 11.3.14. Bristol-Myers Squibb Company
- 11.3.15. Roche Holding AG
- 11.3.1. Novo Nordisk A/S
Chapter 12. Research Process
- 12.1. Research Process
- 12.1.1. Data Mining
- 12.1.2. Analysis
- 12.1.3. Market Estimation
- 12.1.4. Validation
- 12.1.5. Publishing
- 12.2. Research Attributes
